About ValenzaBio
ValenzaBio is a company based in Bethesda (United States) founded in 2019 was acquired by ACELYRIN in January 2023.. ValenzaBio has raised $79.37 million across 1 funding round from investors including Fidelity Investments, Pierre Fabre and ACELYRIN. The company has 17 employees as of December 31, 2022. ValenzaBio operates in a competitive market with competitors including Biogen, ADMA Biologics, Kymeratx, BioNTech and Generate Biomedicines, among others.
- Headquarter Bethesda, United States
- Employees 17 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$79.37 M (USD)
in 1 rounds
-
Latest Funding Round
$79.37 M (USD), Series A
Apr 08, 2021
-
Investors
Fidelity Investments
& 5 more
-
Employee Count
17
as on Dec 31, 2022
-
Acquired by
ACELYRIN
(Jan 06, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of ValenzaBio
ValenzaBio has successfully raised a total of $79.37M through 1 strategic funding round. The most recent funding activity was a Series A round of $79.37 million completed in April 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $79.4M
-
First Round
First Round
(08 Apr 2021)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2021 | Amount | Series A - ValenzaBio | Valuation | Fidelity Investments , Ikarian Capital |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in ValenzaBio
ValenzaBio has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Pierre Fabre and ACELYRIN. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment services are offered by Ikarian Capital for various sectors.
|
Founded Year | Domain | Location | |
|
Multiple sectors are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
Provider of brokerage accounts, retirement planning, wealth management, and trading platforms
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by ValenzaBio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - ValenzaBio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Valenzabio Comparisons
Competitors of ValenzaBio
ValenzaBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, ADMA Biologics, Kymeratx, BioNTech and Generate Biomedicines, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Plasma-based biologics are developed for immune deficiency and infectious diseases.
|
|
| domain | founded_year | HQ Location |
Small molecule protein degraders are developed for various disorders.
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics for cancer and other diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Valenzabio
Frequently Asked Questions about ValenzaBio
When was ValenzaBio founded?
ValenzaBio was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Where is ValenzaBio located?
ValenzaBio is headquartered in Bethesda, United States. It is registered at Bethesda, Maryland, United States.
Is ValenzaBio a funded company?
ValenzaBio is a funded company, having raised a total of $79.37M across 1 funding round to date. The company's 1st funding round was a Series A of $79.37M, raised on Apr 08, 2021.
How many employees does ValenzaBio have?
As of Dec 31, 2022, the latest employee count at ValenzaBio is 17.
What does ValenzaBio do?
Founded in 2019 and based in Bethesda, United States, treatments for autoimmune and inflammatory diseases are developed by ValenzaBio in the biotechnology sector. Operations center on monoclonal antibodies, with VB119 designed as an IgG1 that binds to the CD-19 B-cell receptor for membranous nephropathy management. VB421 is engineered to bind IGF-1R at sub-50 pM affinity, targeting thyroid eye disease.
Who are the top competitors of ValenzaBio?
ValenzaBio's top competitors include ADMA Biologics, BioNTech and Vera Therapeutics.
Who are ValenzaBio's investors?
ValenzaBio has 6 investors. Key investors include Fidelity Investments, Pierre Fabre, ACELYRIN, Citadel, and Janus Henderson Investors.